Perkins Capital Management Inc. Grows Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Perkins Capital Management Inc. increased its stake in Cryoport, Inc. (NASDAQ:CYRX) by 1,286.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,400 shares of the company’s stock after purchasing an additional 147,900 shares during the quarter. Perkins Capital Management Inc. owned 0.32% of Cryoport worth $1,240,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in shares of Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after acquiring an additional 1,764 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Cryoport by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after purchasing an additional 2,226 shares during the period. Penbrook Management LLC raised its holdings in Cryoport by 6.0% in the 4th quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock worth $409,000 after purchasing an additional 2,975 shares during the period. American Century Companies Inc. lifted its position in Cryoport by 12.0% during the fourth quarter. American Century Companies Inc. now owns 51,443 shares of the company’s stock valued at $400,000 after purchasing an additional 5,508 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in Cryoport during the fourth quarter valued at about $64,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of Cryoport stock opened at $5.69 on Monday. The company has a market capitalization of $283.99 million, a price-to-earnings ratio of -1.68 and a beta of 1.67. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock’s 50-day simple moving average is $6.81 and its 200-day simple moving average is $7.37. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $20.11.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. As a group, analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 14,431 shares of company stock valued at $80,884. 10.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CYRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim started coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Cryoport presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.